|
Lowering the boom on lower-risk myelodysplastic syndromes |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Monitoring and treatment of MDS in genetically susceptible persons |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Genetic predisposition to MDS: diagnosis and management |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
Jul 2020 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic syndromes with ring sideroblasts |
Oct 2023 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
|
Controversies on the Consequences of Iron Overload and Chelation in MDS |
May 2020 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
|
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
Apr 2019 |
Haemotologica |
Myelodysplastic Syndromes (MDS) |
|
Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study |
Apr 2019 |
Haematologica |
Aplastic Anemia |
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
Jan 2020 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria |
Oct 2020 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
